ClinicalTrials.gg
Not yet recruitingNCT07937475ReMonit YoungUpdated Nov 16, 2026

Remote Monitoring in Young Adults With Inflammatory Joint Disease

An interventional study of Remote digital follow-up and Conventional hospital-based follow-up in Rheumatoid Arthritis (RA, Juvenile Idiopathic Arthritis (JIA) and Spondyloarthritis (SpA), sponsored by Diakonhjemmet Hospital. Not yet recruiting at 1 site in Norway. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Diakonhjemmet Hospital · Not applicable, Interventional, and Health services research

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Arthritis, Rheumatoid by Diakonhjemmet Hospital — 4 open to participants now, 8 under way, none of them phase 3. Arthritis, Rheumatoid · Diakonhjemmet Hospital.

Planned enrollment
6th of 10
148 · median 188
Started
2026
the only one that year
No phase
7 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Arthritis, Rheumatoid by Diakonhjemmet Hospital, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 7 with no phase, and was the 15th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 15 studies in Arthritis, Rheumatoid by Diakonhjemmet Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arthritis, Rheumatoid by Diakonhjemmet Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.

The main questions it aims to answer are:

  • Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months?
  • Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)

Participants will:

  • Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital .
  • Complete questionnaires about their symptoms, health, and treatment during the study.
  • Attend appointments with a rheumatologist at the start of the study and at study end at 24 months.
  • If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform.
  • If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.

This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .

Read the detailed description

This project addresses follow-up care for young adults with an inflammatory joint disease (IJD), a group facing the challenge of the transition from pediatric to adult care and with variable treatment adherence. Remote digital follow-up may support timely detection of disease worsening, self-management, and efficient use of healthcare resources. However, there is limited evidence on whether remote follow-up is non-inferior to conventional in-person follow-up at the hospital in terms of disease control, particularly in this patient group .

The main objective is to assess whether a remote, digitally supported follow-up strategy is non-inferior to conventional scheduled in-person follow-up (outpatient care) regarding maintenance of low disease activity at 24 months in young adults (18-30 years) with juvenile idiopathic arthritis, rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who are in low disease activity and at a stable dosage of disease-modifying antirheumatic drug (DMARD) treatment.

Primary endpoint: Low disease activity at 24 months, defined by diagnosis-specific composite disease activity criteria. Non-inferiority is concluded if the lower bound of the two-sided 95% confidence interval for the difference (remote minus conventional) is above -15 percentage points.

Secondary endpoints include safety (disease flares, unscheduled visits due to worsening, adverse events, medication changes), patient satisfaction, medication adherence, composite disease activity scores, and inflammatory markers. Exploratory endpoints include healthcare costs and cost-effectiveness, travel-related carbon footprint of in-person consultations, user experience, and engagement with the digital platform.

Study design: A two-arm, parallel-group, open-label, non-inferiority study where participants are randomized 1:1 to remote digital follow-up or conventional in-person follow-up, stratified by diagnosis and medication-delivery mode (hospital-administered intravenous versus self-administered treatment). The statistician performing the primary analysis will be blinded to allocation. Duration of follow-up is 24 months. All participants continue their prescribed antirheumatic treatment.

Intervention: Remote follow-up using the MyDignio digital platform. Every three months, participants answer six triage questions on symptoms, adherence, side effects, treatment interruptions, impact on daily life, and need for a consultation with a health professional. Responses indicating increased symptoms, reduced adherence, side effects, treatment interruptions, or request for contact generate an alert. A study nurse then contacts the participant and arranges a telephone or in-person consultation within two weeks if needed. Participants can also send messages, which are reviewed 2-3 times/week. Scheduled contacts are rheumatologist consultations at baseline and 24 months and a nurse consultation at 12 months.

Conventional follow-up: Standard rheumatology in-patient follow-up care with rheumatologist assessments at baseline, 12, and 24 months and consultations with a nurse at 6 and 18 months. In both arms, additional consultations are arranged when clinically indicated, using the same criteria.

03

Conditions studied

  • Rheumatoid Arthritis (RA
  • Juvenile Idiopathic Arthritis (JIA)
  • Spondyloarthritis (SpA)
  • Psoriatic Arthritis (PsA)

Keywords

  • Remote monitoring
  • Digital health
  • Patient-initiated follow-up
  • Health services research
  • Rheumatology
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biological male or female aged 18-30 years at the time of
  • Clinical diagnosis of JIA, RA, SpA, or PsA
  • Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted.
  • Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS\< 2.1, DAPSA≤14)
  • Ability to understand Norwegian
  • Capable of providing written informed consent
  • Access to a smartphone or tablet compatible with installation of the Dignio application

Exclusion criteria

Exclusion Criteria:

Major co-morbidities, such as severe , severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease ( class III or IV), severe respiratory diseases, and/or cirrhosis

  • Indications of active tuberculosis (TB)
  • Pregnant and/or breastfeeding
  • Stills disease (systemic JIA)
  • Currently enrolled in a different RCT
  • Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or (GFR) \<40 mL/min/1.73 m2
  • Abnormal liver function (defined as (ALT) >3x upper normal limit), active or recent hepatitis
  • Leukopenia and/or thrombocytopenia
  • Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible.
  • Planned pregnancy during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Remote digital follow-up

    Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment.

    Other: Remote digital follow-up

  • Active comparator
    Conventional hospital-based follow-up

    Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment

    Other: Conventional hospital-based follow-up

Interventions

  • OtherRemote digital follow-up

    Remote follow-up for 24 months using the MyDignio digital platform on the participant's smartphone or tablet, after training from the study team. Every three months, participants answer triage questions covering: * increased symptoms from their rheumatic disease * whether medication is taken as agreed with their rheumatologist * new medication side effects * recent interruptions in treatment * increased impact of symptoms on daily life * need for contact with a healthcare professional Any response indicating a potential problem generates an automatic alert, and the participant can describe the issue in free text. For each alert, a study nurse contacts the participant and, if needed, arranges a telephone or in-person consultation within two weeks. Participants may also send chat messages, which do not generate alert and are reviewed 2-3 times/week; the platform is not an emergency service. Scheduled contacts: consultations with a rheumatologist at baseline and 24 months, and a consult

  • OtherConventional hospital-based follow-up

    Convetional rheumatology outpatient follow-up for 24 months, with rheumatologist in-person assessments at baseline, 12 and 24 months and consultations with a nurse, in-person or by telephone, at 6 and 18 months. Participants may contact the study nurse between scheduled visits, and additional consultations are arranged when clinically indicated, using the same criteria as in the remote arm. Participants continue their prescribed antirheumatic treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of participants in low disease activity

    Assessed using a composite score specific to diagnosis. For all scores, higher values indicate higher disease activity. Participants are considered to be in low disease activity (including remission) if they meet the following criteria: JIA: Juvenile Arthritis Disease Activity Score 27 (JADAS27) ≤ 2.7; RA: Disease Activity Score 28 joints ≤3.2; SpA: Ankylosing Spondylitis Disease Activity Score \<2.1; PsA: Disease Activity in Psoriatic Arthritis (DAPSA) ≤14.

    Time frame: Baseline and 24 months

Secondary outcomes

  1. Number of participants with at least one disease flare

    Number of participants with ≥1 disease flare. Flare is defined as: JIA: JADAS27 increase ≥1.7 from baseline and ≥1 active joint; RA: DAS28 increase ≥1.2 from baseline, or ≥0.6 if DAS28 ≥3.2; SpA: ASDAS increase ≥0.9 from baseline; PsA: DAPSA increase ≥7 from baseline; or, for all diagnoses, consensus between treating physician and participant that a clinically significant flare has occurred requiring intensified antirheumatic treatment. Assessed at scheduled and unscheduled visits.

    Time frame: 0-24 months

  2. Number of unscheduled rheumatology visits due to disease worsening

    Number of unscheduled telephone or in-person rheumatology consultations due to worsening of the participant's inflammatory joint disease

    Time frame: 0-24 months

  3. Number and type of adverse events

    Number and nature of adverse events and serious adverse events since the previous assessment

    Time frame: 12 and 24 months

  4. Number of participants with changes in anti-rheumatic medication

    Number of participants with changes in antirheumatic treatment since the previous assessment

    Time frame: 12 and 24 months

  5. Number and type of medication-related side effects

    Number and type of side effects attributed to medication since the previous assessment

    Time frame: 12 and 24 months

  6. Proportion of participants using NSAIDs and/or analgesics

    Proportion of participants reporting use of NSAIDS and/or analgesics

    Time frame: Baseline, 12, and 24 months

  7. Number of antibiotic prescriptions dispensed

    Number of antibiotic prescriptions dispensed to each participant since the previous assessment, obtained from the Norwegian Prescription Database

    Time frame: 12 and 24 months

  8. Overall satisfaction with care

    A single item from the Nordic Patient Experiences Questionnaire (NORPEQ) on overall satisfaction with care, rated on a five-point Likert scale from very satisfied to very dissatisfied, lower score indicates higher satisfaction

    Time frame: Baseline, 12, and 24 months

  9. Medication adherence assessed with the MARS-5 questionnaire

    Self-reported adherence to anti-rheumatic medication measured with the Medication Adherence Report Scale-5 (MARS-5), consisting of five items each scored 1-5 (total range 5-25). Higher scores indicate greater adherence. Participants with a score ≥23 are classified as adherent.

    Time frame: Baseline, 12, and 24 months

  10. Diagnosis-specific composite disease activity score

    Disease activity is assessed using a composite score specific to diagnosis (JADAS27 for JIA, DAS28 for RA, ASDAS for SpA and DAPSA for PsA). DAS28 assessed in addition to JADAS27 in participants with JIA. Higher scores indicate more disease activity.

    Time frame: Baseline, 12, and 24 months

  11. C-reactive protein (CRP)

    CRP (mg/L), with higher values indicating more inflammation

    Time frame: Baseline, 12, and 24 months

  12. Erythrocyte sedimentation rate (ESR)

    ESR (mm/h), with higher values indicating more inflammation

    Time frame: Baseline, 12, and 24 months

Other outcomes

  1. Patient-reported pain

    General pain last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no pain) to 10 (worst possible pain)

    Time frame: Baseline, 12, and 24 months

  2. Patient-reported fatigue

    General fatigue last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no fatigue) to 10 (worst possible fatigue)

    Time frame: Baseline, 12, and 24 months

  3. Patient global assessment of disease activity

    The patient global assessment of disease activity (last 7 days) component of the diagnosis-specific composite measure, standardized to NRS 0-10, with higher scores indicating more disease activity

    Time frame: Baseline, 12, and 24 months

  4. Health-related quality of life as assessed by the EuroQol 5 Dimension 5 Level questionnaire

    Health-related quality of life measured with EuroQol Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Summarized as an index value with higher values indicating higher quality of life.

    Time frame: Baseline, 12, and 24 months

  5. Self-reported overall health

    EuroQol single item. Reported on a visual analog scale 0-100, higher value indicates greater self-assessed overall health status

    Time frame: Baseline, 12, and 24 months

  6. Impairment in non-work activities as assessed by the Work Productivity and Activity Impairment Questionnaire (WPAI)

    Item 6 of the Work Productivity and Activity Impairment questionnaire (WPAI) , converted to 0-100% impairment in non-work activities. Higher percentage indicates greater impairment.

    Time frame: Baseline, 12, and 24 months

  7. Mental well-being as assessed by the WHO-5 Well-Being Index

    Self-reported mental well-being measured with the five-item WHO-5 Well-Being Index. Raw score 0-25, with higher scores indicating better wellbeing

    Time frame: Baseline, 12, and 24 months

  8. Number of hospital contacts

    Number of hospital contacts (outpatient visits and admissions), obtained from the Norwegian Patient Register

    Time frame: 0-24 months

  9. Number of dispensed prescriptions of anti-rheumatic medication

    Number and type of anti-rheumatic medication prescriptions dispensed, obtained from the Norwegian Prescription Database (NorPD)\[N

    Time frame: 0-24 months

  10. Number of primary care contacts

    Number of contacts with primary care (e.g. general practitioner and emergency primary care), obtained from the Control and Payment of Health Reimbursements (KUHR) database

    Time frame: 0-24 months

  11. Costs related to hospital visits

    Self-reported travel distance in kilometers to the hospital.

    Time frame: Baseline

  12. Costs related to hospital visits

    Self-reported way of transport to the hospital; walking or bicycling/private car/public transportation/taxi/airplane/other.

    Time frame: Baseline

  13. Proportion of participants in paid work who need to take time off work for rheumatology consultations

    Participants in paid work report whether they need to take time off work to attend rheumatology consultations at the hospital, whether in person, by telephone, or by video (yes/no). Participants who are not in paid work are not asked to answer this item.

    Time frame: Baseline

  14. Incremental cost-effectiveness ratio

    Within-trial cost-utility analysis. Quality-adjusted life years (QALYs) estimated from EQ-5D-5L, results presented as incremental cost per QALY gained

    Time frame: 0-24 months

  15. Patient satisfaction with remote monitoring

    Service User Technology Acceptability Questionnaire (SUTAQ) reported by the Remote monitoring group. 22 items in 5 subscales. Score range 1-6. Higher scores in subscales 1,2 and 5/lower scores in subscales 3 and 4 indicate higher acceptability with telehealth.

    Time frame: 12 and 24 months

  16. Completion of scheduled triage questionnaire and use of the digital platform

    Proportion of scheduled triage questionnaires (3, 6, 9, 12, 15, 18 and 21 months) completed, and patterns of interaction with the MyDignio platform. Asessed in the remote follow-up group only

    Time frame: 3-21 months

  17. Number of withdrawals or early discontinuation

    Number of withdrawals/early discontinuation

    Time frame: 0-24 months

  18. Patient-reported self-efficacy for using different digital devices, secure login and digital health services

    Self-efficacy/confidence in using smartphone, tablet, computer, app's, secure login and digital health services. 6 items with Likert scale response categories: Never used, Very bad, Bad, Neither good nor bad, Good, Very good. Score range 0-5; higher scores indicate higher self-efficacy.

    Time frame: Baseline

  19. eHealth literacy

    20 items from 4 domains of the eHealth Literacy Questionnaire (eHLQ). Four-point response scale, sum domain score range 1-4. Lower scores indicate lower eHealth literacy.

    Time frame: Baseline

  20. Travel-related carbon footprint of in-person consultations

    Estimated greenhouse gas emissions (kg CO2-equivalents per participant) from travel to and from in-person rheumatology consultations. Calculated from the number of in-person consultations, self-reported travel distance and usual mode of transport, and emission factors per passenger-kilometre.

    Time frame: 0-24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 292 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937475
Lead sponsor
Diakonhjemmet Hospital
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Nina Østerås, PhD
Contact
nina.osteras@diakonsyk.no
92086465 ext. +47

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion